biogen - Search News

Eisai, Biogen and CHMP

BioSpace · 20h

Biogen, Eisai Continue Leqembi’s European Rally as CHMP Reaffirms Positive Opinion

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that will apply to all EU member states as well as Norway, Liechtenstein and Iceland.

EU regulator reiterates positive recommendation for Eisai-Biogen's Alzheimer's drug

The European Union's medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen's Alzheimer's drug, Leqembi, after concluding a safety review.

Business Insider · 3d

Biogen, Eisai announces CHMP of EMA reaffirmed positive opinion of lecanemab

Eisai (ESAIY) and Biogen (BIIB) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA,

MarketWatch · 3d

Biogen, Eisai: CHMP Reaffirms Backing of Leqembi Alzheimer's Drug

The companies on Friday said the European Commission, which had asked the panel to consider information on the safety of Leqembi that became available after it adopted a positive opinion in November,

Reuters on MSN · 3d

EU regulator completes safety review of Eisai-Biogen's Alzheimer's drug without changes

The European Union's drugs regulator said on Friday it concluded a review into the safety of Eisai and Biogen's Alzheimer's drug Leqembi without finding the need for any changes to the drug's status.

11h

Biogen Inc. (BIIB) CEO Chris Viehbacher presents at TD Cowen 45th Annual Health Care Conference (Transcript)

TD Cowen 45th Annual Health Care Conference March 3, 2025 9:10 AM ETCompany ParticipantsChris Viehbacher - CEOConference ...

13don MSN

Biogen Bets Up to $550 Million for Rights to Epilepsy Drug

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the ...

FierceBiotech13d

Biogen pays Stoke $165M, bagging Dravet prospect to fire up late-phase pipeline

The deal, which features up to $385 million in milestones, gives Biogen exclusive rights to commercialize Stoke’s ...

13d

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

Under the terms of the deal, Bedford, Mass.-based Stoke STOK will retain exclusive rights for the treatment called ...

Biogen partners with Stoke Therapeutics on drug for severe epilepsy

Biogen and Stoke Therapeutics have signed a deal to co-develop and sell Stoke’s experimental drug for Dravet syndrome, ...

BioPharma Dive13d

Biogen buys rights to Stoke’s rare epilepsy drug

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

13d

Biogen continues dealmaking buzz with Stoke Therapeutics

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

CHMP again backs Leqembi amid flurry of approval recommendations

Following a flurry of activity at this month’s meeting of the European Medicines Agency’s Committee for Medicinal Products ...

StockStory.org on MSN1d

3 Reasons BIIB is Risky and 1 Stock to Buy Instead

Shareholders of Biogen would probably like to forget the past six months even happened. The stock dropped 31.4% and now ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results